The Gly82Ser Polymorphism of the Receptor of Advanced Glycation End Product (RAGE) Gene Is Not Associated With Type 1 or Type 2 Diabetes in a Brazilian Population
- Carolina L. Naka, BSC,
- Geraldo Picheth, MSC,
- Vânia Manfredini Alcântera, PHD,
- Rosangela R. Réa, MD,
- Eleidi A. Chautard-Freire-Maia, PHD,
- Fábio de Oliveira Pedrosa, PHD,
- Tania Leme da Rocha Martinez, PHD and
- Emanuel M. Souza, PHD
- Department of Biochemistry and Molecular Biology, Federal University of Parana, Curitiba-PR, Brazil
- Address correspondence and reprint requests to Geraldo Picheth, MsC, Department of Biochemistry and Molecular Biology, Federal University of Parana, 81531990, P.O. Box 19046, Curitiba-PR, Brazil. E-mail: gpicheth{at}ufpr.br
In diabetes, the levels of advanced glycation end products (AGEs) increase as a result of chronic hyperglycemia (1). The best-characterized receptor for AGEs is RAGE. The AGE-RAGE interaction mediates activation and secretion of various cytokines via activation of factors such as the nuclear factor-κB, leading to a proinflammatory process (1). A guanine-to-adenine single nucleotide polymorphism at codon 82 (GGC→AGC) located in exon 3 of RAGE causes the amino acid change glycine to serine (Gly82Ser or G82S polymorphism) within the putative ligand-binding domain of the protein (2). The RAGE Ser82 isoform has been suggested to upregulate the inflammatory response upon engagement of S100/calgranulins, thereby contributing to the enhancement of proinflammatory mechanisms (3). The aim of this study was to investigate the association of the RAGE polymorphism Gly82Ser with type 1 and type 2 diabetes in a Brazilian population compared with a nondiabetic sample.
RESEARCH DESIGN AND METHODS
The ethnic composition of this unrelated sample was 65.4% Euro Brazilian, 33.8% African Brazilian, and 0.8% Asians. The …
